Research programme: solid tumour immunotherapy - Aptose Biosciences

Drug Profile

Research programme: solid tumour immunotherapy - Aptose Biosciences

Alternative Names: IL-17E; IL-25; interleukin-17E

Latest Information Update: 04 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lorus Therapeutics
  • Developer Aptose Biosciences; Cancer Research Technology
  • Class Interleukins
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 02 Sep 2014 Lorus Therapeutics is now called Aptose Biosciences
  • 27 Nov 2012 Lorus Therapeutics partners with Cancer Research Technology in the UK for further preclinical development of IL 17E and to conduct a phase I trial
  • 27 Nov 2012 Preclinical trials in Solid tumours in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top